Dysregulated m 6 A via compensatory arginine methylation primes premalignancy in metabolic dysfunction–associated steatotic liver disease
Science Advances · 2026
DOI: 10.1126/sciadv.aec5094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Geun-Woo D Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Sciences, Korea University, Seoul 02841, Korea. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Arginine, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Science and ICT, South Korea, Graduate School, Prince of Songkla University.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) originates from premalignant disease-associated hepatocytes (daHeps) that emerge during the progression of metabolic dysfunction–associated steatotic liver disease (MASLD) to metabolic dysfunction–associated steatohepatitis (MASH). As daHeps are compensatorily primed by metabolic stress, we reproduced the accelerated progression of MASLD-associated HCC in mice by phenocopying the decreased expression of a metabolic regulator, protein arginine methyltransferase 1 (PRMT1). In Prmt1 liver-specific knockout (LKO), m 6 A-mediated changes in mRNA stability reprogram the transcriptome via paralog compensation; increased PRMT6 activates m 6 A methyltransferases by inducing asymmetric arginine dimethylation of METTL3. This event enhances global m 6 A deposition that leads to the down-regulation of Keap1 , which would trigger the NRF2 axis, promoting premalignancy; under diet- and chemical-induced stress, the incidence of steatohepatitic HCC was increased, clinically correlating with the PRMT-METTL3-NRF2 pathway. Together, we propose that compensatory arginine methylation primes MASLD-associated HCC by modulating m 6 A-mediated transcriptome and NRF2 regulatory pathways as adaptive defenses against metabolic and oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Life Sciences, Korea University, Seoul 02841, Korea.
- KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Korea.
- Department of Molecular and Life Science, Hanyang University, Ansan, Korea.
- Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul 03760, Korea.
- Korea Model Animal Priority Center, Seoul National University, Seoul 08826, Korea.
- Department of Biomedical Sciences, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul 03760, Korea.
ORCID-Profile: Geun-Woo D Kim, Dahee Choi, Soo-Young Kim, Haengdueng Jeong, Geon Kang, Sangkyeong Eom, Jinyoung Park, Insook Yang, Je Kyung Sung, Ki Taek Nam, Young Nyun Park, Sung Wook Chi, Seung-Hoi Koo
Förderung
- Ministry of Science and ICT, South Korea
- Graduate School, Prince of Songkla University
Zitieren
APA
Kim, G. D., Choi, D., Kim, S. Y., Jeong, H., Kang, G., Eom, S. J., Eom, S., Park, J., Lee, H. S., Yang, I., Sung, J. K., Nam, K. T., Park, Y. N., Chi, S. W., & Koo, S. H. (2026). Dysregulated m 6 A via compensatory arginine methylation primes premalignancy in metabolic dysfunction–associated steatotic liver disease. Science Advances. https://doi.org/10.1126/sciadv.aec5094
Vancouver
Kim GD, Choi D, Kim SY, Jeong H, Kang G, Eom SJ, et al. Dysregulated m 6 A via compensatory arginine methylation primes premalignancy in metabolic dysfunction–associated steatotic liver disease. Science Advances. 2026. doi:10.1126/sciadv.aec5094
BibTeX
@article{Kim2026,
author = {Kim, Geun-Woo D and Choi, Dahee and Kim, Soo-Young and Jeong, Haengdueng and Kang, Geon and Eom, So Jung and Eom, Sangkyeong and Park, Jinyoung and Lee, Hye-Sook and Yang, Insook and Sung, Je Kyung and Nam, Ki Taek and Park, Young Nyun and Chi, Sung Wook and Koo, Seung-Hoi},
title = {Dysregulated m 6 A via compensatory arginine methylation primes premalignancy in metabolic dysfunction–associated steatotic liver disease},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aec5094}
}
EUVIMED